Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 7, 2020Modern Rheumatology

Up-regulation of IGF-1, RANTES and VEGF in patients with anti-centromere antibody-positive early/mild systemic sclerosis

View Full Paper
Ask AI
Bookmark
Share

Authors

KTKayoko TabataNMNaoya MikitaMYMisaki Yasutake

Discussion

Loading...

Member takes

Overview

Observational study reveals elevated IGF-1, RANTES, and VEGF in anti-centromere antibody-positive early systemic sclerosis, indicating potential utility as biomarkers for early disease progression.

Key Points

  • To compare angiogenic cytokine expression profiles across clinical stages in anti-centromere antibody-positive systemic sclerosis to identify potential markers of progression.
  • Stratified nine anti-centromere antibody-positive patients (N=9) into three groups: pre-clinical stage (group 1), early/mild systemic sclerosis (group 2), and typical limited cutaneous systemic sclerosis (group 3).
  • Quantified serum expression levels of 20 angiogenic cytokines across patient groups using a membrane array.
  • Ten cytokines (EGF, ENA-78, bFGF, IGF-I, IL-8, MCP-1, TGF-β1, thrombopoietin, VEGF, and VEGF-D) increased more than twofold in group 2 relative to group 1.
  • Serum levels of IGF-1, RANTES, and VEGF differed significantly between group 1 and group 2, VEGF differed significantly between group 1 and group 3, and IGF-1 correlated with RANTES (r = 0.721, p = 0.028).

Cite This Study

Tabata et al. (2020) studied this question.

synapsesocial.com/papers/6a751feba44b96c1f7dbef5chttps://doi.org/10.1080/14397595.2020.1726599
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Angiogenic and intraplatelet growth biomarkers in systemic sclerosis2026
  2. 2Analysis of the Dynamics of Clinical Parameters and Serum Angiogenic Factors in Systemic Sclerosis Patients Undergoing Tocilizumab Treatment2026
  3. 3Effect of Vasodilator And Immunosuppressive Therapy On The Endothelial Dysfunction In Patients With Systemic Sclerosis2021
  4. 4Dysregulation of circulating collagen turnover markers in very early systemic sclerosis2024 · 4 citations
  5. 5Serum levels of <scp>AGGF1</scp>: Potential association with cutaneous and cardiopulmonary involvements in systemic sclerosis2024 · 2 citations